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Simple Summary: The relationship between cancer and blood clotting has been well established.
The activation of blood coagulation proteins regulates the fate of cells and is known to be used by
cancer cells to enhance survival and proliferation. Cells strictly regulate the initiation of coagulation
through controlling the action of the protein “tissue factor (TF)”. In addition to initiating clotting,
TF also acts as a deciding factor to determine the extent of damage and instructs cells to proliferate
and repair or, when severely damaged, to die. Therefore, normal cells keep TF in a dormant state,
achieved through mechanisms called “TF encryption”. Understanding the mechanisms by which
the cells control the activity of TF is crucial, especially since cancer cells bypass these regulatory
mechanisms, ensuring survival and tumour growth. This study has elucidated essential molecular
mechanisms by which cells regulate TF clotting activity, and also the cellular signals arising from
these.
Abstract: In this study, the role of de-palmitoylation of tissue factor (TF) in the decryption of its
activity was explored. TF-tGFP constructs were prepared by mutagenesis-substitution at Cys245
to prevent or mimic palmitolyation. Additionally, to reduce TF de-palmitoylation, the expression
of palmitoyl-protein thioesterases (PPT) was suppressed. Other TF mutants were prepared with
altered flexibility, hydrophobicity or length of the transmembrane domain. The outcome of these
alterations on fXa-generation, fVIIa binding, Ser253 phosphorylation and TF-microvesicle release
were assessed in endothelial cells, and the influence on endothelial and MCF-7 cell proliferation and
apoptosis was analysed. Preventing TF palmitoylation (TFSer245-tGFP), increasing the hydropho-
bicity (TFPhe241-tGFP) or lengthening (TFLongTM-tGFP) of the transmembrane domain enhanced
fXa-generation in resting cells compared to cells expressing TFWt-tGFP, but fXa-generation was not
further increased following PAR2 activation. Extending the available length of the transmembrane
domain enhanced the TF-tGFP release within microvesicles and Ser253 phosphorylation and in-
creased cell proliferation. Moreover, prevention of PKCα-mediated Ser253 phosphorylation with
Gö6976 did not preclude fXa-generation. Conversely, reducing the hydrophobicity (TFSer242-tGFP),
shortening (TFShortTM-tGFP) or reducing the flexibility (TFVal225-tGFP) of the transmembrane domain
suppressed fXa-generation, fVIIa-HRP binding and Ser253 phosphorylation following PAR2 activa-
tion. PPT knock-down or mimicking palmitoylation (TFPhe245-tGFP) reduced fXa-generation without
affecting fVIIa binding. This study has for the first time shown that TF procoagulant activity is
regulated through de-palmitoylation, which alters the orientation of its transmembrane domain and
is independent of TF phosphorylation. However, Ser253 phosphorylation is facilitated by changes in
the orientation of the transmembrane domain and can induce TF-cellular signalling that influences
cellular proliferation/apoptosis.
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1. Introduction
Uncontrolled coagulation arising from tissue factor (TF) activity has been implicated
in both arterial and venous thrombosis with potentially fatal outcomes [1,2]. TF encryption
refers to the post-translational suppression of TF procoagulant activity on the surface of
cells. Unperturbed or non-activated cells present little TF activity despite the presence
of TF antigen on the cell surface. Interestingly, encrypted TF may form a complex with
fVIIa without promoting significant coagulation, and the kinetics of this interaction have
previously been studied [3]. However, it is suggested that the affinity between these
two proteins is amplified following decryption. The mechanism of TF decryption is
not currently understood, although at least four mechanisms have been suggested [4–8].
However, none of these alone is sufficient to explain the observed tight regulation of TF
activity.
TF has a small cytoplasmic domain that has no kinase activity and is not thought
to be required for its procoagulant activity [9,10]. However, Ser253 and Ser258 within
the cytoplasmic domain of TF are phosphorylated following de-palmitoylation of the
cytoplasmic domain [11,12] and are capable of regulating the incorporation of TF into
microvesicles [13]. The role of phosphorylation in the regulation of incorporation of
TF into microvesicles has been characterised [13–17]. Phosphorylation of Ser253 per-
mits the interaction of TF with the cytoskeletal protein filamin-A, which is required
for the trafficking of TF to the site of microvesicle formation [14–16]. Palmitoylation
of Cys245 within the cytoplasmic domain of human TF was one of the earliest post-
translational modifications reported [18] and was suggested to be a means of anchoring TF
in cholesterol-rich lipid rafts [5,6] containing procoagulant phospholipids [4,11,19]. How-
ever, experimental data indicated that the procoagulant activity of TF is reduced following
palmitoylation [11,12,19]. It has also been shown that de-palmitoylation of TF enhances
and precedes TF phosphorylation [11]. We have recently shown that subsequent TF phos-
phorylation at Ser253 results in increased TF procoagulant activity [14] as well as TF release
within cell-derived microvesicles [13]. Other studies have shown that the association of
TF with lipid-raft occurs as part of the mechanism of TF release into microvesicles [14,20]
and control of TF procoagulant activity [21–23]. In this study, we hypothesised that the
de-palmitoylation of TF alters the orientation of the transmembrane domain of TF within
the plasma membrane. This in turn could permit the transfer and association of TF with
thicker membrane regions such as cholesterol-rich microdomains, which contain lipids
that support TF activity. We also explored the association of these events with TF-mediated
proliferative and pro-apoptotic signals.
2. Material and Methods
2.1. Site-Directed Mutagenesis
The pCMV6-Ac-TF-tGFP plasmid DNA (OriGene/Insight Biotechnology, Wembley,
UK) was used to express wild-type or variant forms of TF, as previously described [13,24,25].
Preparations of pCMV6-Ac-tGFP (control) and pCMV6-Ac-TFAla253-tGFP were described
previously [13]. Single amino acid-substitutions or deletions were carried out to obtain
the mutants, as illustrated in Table 1, using the primer pairs indicated. All procedures
were carried out using the Q5-site directed mutagenesis kit (New England Biolabs, Hitchin,
UK) according to the manufacturer’s procedure. All mutants were verified by sequencing
(Eurofin MWG, Wolverhampton, UK).
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Table 1. The list of TF variants and DNA primers used for mutagenesis.















2.2. Cell Culture, Transfection and Cellular Activation
Human dermal blood primary endothelial cells (HDBEC) and coronary artery endothe-
lial cells (HCAEC) devoid of endogenous TF were cultured in MV media containing 5%
(v/v) foetal calf serum (FCS) and growth supplements (PromoCell, Heidelberg, Germany).
MCF-7 and MDA-MB-231 breast cancer cell lines (ATCC, Teddington, UK) expressing low
and high levels of TF were cultured in EMEM and DMEM, respectively, containing 10%
(v/v) FCS. Cells (5× 105) were seeded out into 48-well plates and transfected with 0.5 µg of
pCMV6-Ac-TF-tGFP plasmid DNA or, alternatively, mutant forms of the plasmid, as shown
in Table 1. Transfection of the cells was carried out using TransIT-2020 (Geneflow, Lichfield,
UK) according to the manufacturer’s instructions. Cells were permitted to express the
proteins for 48 h, and the expression of the TF variants was confirmed by flow cytometry as
before [13,14]. Prior to experiments, cells were pre-adapted to respective serum-free media
for 1 h and then activated by incubation with protease-activated receptor 2-activating
peptide (PAR2-AP); SLIGKV; (20 µM). In some experiments, cells were transfected with a
specific set of SilencerSelect®-siRNA (10 pmol; Life Technologies, Paisley, UK) to suppress
the expression of palmitoyl–protein thioesterase (PPT) 1 and 2 concurrently, or transfected
with a comparable set of control siRNA (10 pmol; Life Technologies) for 48 h prior to activa-
tion. The concentration of siRNA to knock-down PPT1 and PPT2 expression was optimised
by western blot. To block the phosphorylation of TF at Ser253, cells were pre-incubated
with the PKC inhibitor Gö6976 (100 nM; R&D Systems, Abingdon, UK) for 40 min, prior to
activation.
2.3. Cell Proliferation and Apoptosis Assays
Cell numbers were determined by staining with crystal violet as previously de-
scribed [26,27] and calculated from a standard curve. In addition, cellular apoptosis
was quantified using the TiterTACS™ Colorimetric Apoptosis Detection Kit (AMS Biotech-
nology, Abingdon, UK) according to the manufacturer’s instructions [28,29].
2.4. Determination of Microvesicle Density and TF Antigen
The release of microvesicles was examined using the Zymuphen MP-assay kit (Hyphen
BioMed/Quadratech, Epsom, UK) and the microvesicle density was determined from the
standards provided. The properties of the MV were previously confirmed [29,30]. The
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released microvesicle-associated TF antigen was measured using the Quantikine TF-ELISA
kit (R & D Systems) according to the manufacturer’s instructions. Cell surface TF antigen
was measured in situ using an ELISA-based procedure as previously described [15,24].
2.5. Cell-Based Factor Xa-Generation Assay
Cell surface TF-fVIIa activity was measured by modification of previously described
procedures [3,24,31]. Cells (5 × 104) were seeded out into 48-well plates and transfected
with the appropriate wild-type or mutant TF plasmids, as shown in Table 1. The cells were
washed with phosphate-buffered saline (PBS) pH 7.4 and then pre-adapted to serum-free
medium. The cells were incubated with PAR2-AP for up to 60 min and then washed and
incubated with fVIIa (20 nM; Enzyme Research Labs, Swansea, UK) in HEPES-buffered
saline (HBS) pH 7.4, containing 1% (w/v) bovine serum albumin (BSA) and 5 mM CaCl2
(100 µL) for an additional 10 min. Finally, the samples were supplemented with fX (100 nM)
together with fXa substrate (0.2 mM; Hyphen) diluted in the same buffer (100 µL). The
samples were incubated for 60 min to develop the colour. Aliquots (150 µL) were then
transferred to a 96-well plate containing 2% (v/v) acetic acid (50 µL) and the absorptions
were measured immediately at 405 nm. The amount of fXa generated was determined
using a standard curve prepared using fXa (Enzyme Research Labs). To inhibit cell surface
TF activity, cells were pre-incubated with the inhibitory anti-TF antibody HTF1 (40 µg/mL;
eBioscience/Thermo Scientific, Warrington, UK) prior to the addition of fVIIa [15].
2.6. Factor VIIa Binding Assay
In order to measure the binding of fVIIa to cell-surface TF, fVIIa (30 µg) was conjugated
to horseradish peroxidase (HRP) using the Innova Lightning-link HRP kit (Expedeon,
Cambridge, UK). A similar control was also prepared by conjugating BSA (30 µg) to HRP.
After neutralisation of excess HRP, the specificity of the fVIIa to interact with TF was
confirmed as follows; 96-well plates were coated with recombinant Innovin TF (13 ng/mL;
Dade Behring, Deerfield, MA, USA) in PBS containing BSA (1% w/v), or coated with the
vehicle solution alone by incubating overnight at 4 ◦C. In parallel experiments, sets of
endothelial cells (5 × 104) were plated out into 48-well plates and transfected to express
TF-tGFP or tGFP, along with non-transfected cells. All plates were washed with PBS and
incubated with fVIIa-HRP (20 nM) (100 µL) for 15 min. The plates were then washed
three times with PBS, and HRP activity was determined using the TMB One-solution HRP
substrate (200 µL). Aliquots (150 µL) of the substrate were then transferred into fresh
wells containing 2 M H2SO4 (50 µL), and the absorptions were determined at 450 nm.
The amount of bound fVIIa-HRP was determined from a standard curve prepared with a
range of concentrations of fVIIa-HRP (100 µL). To confirm the fVIIa activity of the HRP-
conjugated preparations, fXa-generation potential was determined on both endothelial cells
transfected to express TF and also immobilised-recombinant TF using a range of fVIIa-HRP
concentrations (0–10 nM) and compared to fXa generation using unlabelled-fVIIa.
2.7. Immunoprecipitation of TF and Western Blot Analysis of TF Phosphorylation
TF-tGFP was immunoprecipitated from cells lysed in PhosphoSafe buffer (Novagen/
Merck Millipore, Watford, UK) using anti-tGFP-magnetic beads (clone 2H8) (25 µL, Ori-
Gene/Insight Biotechnology) or, in some cases, using anti-TF antibody (HTF1) followed
by protein A-magnetic bead purification, as previously described [24,25]. The samples
were separated by SDS-PAGE, transferred onto nitrocellulose membranes and probed
with a rabbit anti-TF antibody (FL295) (Santa Cruz Biotechnology, Heidelberg, Germany)
diluted 1:4000 (v/v) in TBST. The membranes were developed with goat anti-rabbit al-
kaline phosphatase-conjugated antibody (Santa Cruz), diluted 1:4000 (v/v), and bands
were visualised using the Western Blue stabilised alkaline phosphatase-substrate (Promega,
Southampton, UK). Phosphorylation of TF on Ser253 was detected in the immunoprecipi-
tated samples using a rabbit anti-phospho-PKC-substrate motif antibody (Cell Signalling
Technology) diluted 1:2000 (v/v) in TBST buffer and detected as above. Analysis of PPT1
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and PPT2 expression in cell lysates with and without siRNA-mediated silencing of PPT
was carried out using rabbit anti-human PPT1 and PPT2 antibodies (CloudClone/Insight
Biotechnology, Wembley, UK) diluted 1:2000 (v/v) in TBST and detected as above.
2.8. Confocal Microscopy
HDBEC (5 × 104) were seeded out into 35 mm glass-based µ-dishes (InVitro Scien-
tific/Cellvis, Sunnyvale, CA, USA) and transfected to express wild-type or variants of
TF-tGFP [14,31]. In some experiments, the cells were co-transfected with siRNA to silence
the expression of PPT1 and PPT2, concurrently. Sets of cells were activated with PAR2-AP
for 30 min and then fixed and labelled with DAPI (2 µg/mL) [14,31]. The samples were
then analysed by confocal microscopy at room temperature using a Zeiss LSM 710 confocal
microscope with a ×63 water immersion objective. Images were acquired using the ZEN
software (Carl Zeiss Ltd., Welwyn Garden City, UK) and analysis of the aggregate sizes was
carried out using the ImagePro Plus software (Media Cybernetics, Bethesda, MD, USA).
2.9. Statistical Analysis
All data represent the calculated mean values from the number of experiments stated
in each figure legend ± the calculated standard error of the mean. Statistical analysis was
carried out using the Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL,
USA). Significance was determined using one-way ANOVA (analysis of variance) and
Tukey’s honest significance test or, where appropriate, by paired t-test.
3. Results
3.1. Validation of the fVIIa-HRP Conjugation and fVIIa Activity
Prior to usage, the ability of the fVIIa-HRP conjugate preparation to bind to recom-
binant TF (Supplementary Figure S1A) and cell surface TFWt-tGFP (Supplementary Fig-
ure S1B) was confirmed in human primary endothelial cells. Additionally, fVIIa-HRP
and non-conjugated fVIIa exhibited similar fXa-generation activities (Supplementary Fig-
ure S1C).
3.2. Non-Active/Encrypted TF Is Capable of Binding fVIIa without Increasing Procoagulant
Activity
The activation of cells by incubation with the PAR2-agonist peptide is a reproducible
procedure [13,14] that permits the accurate measurement of changes in fXa-generation
in a short period, which was imperative to the success of this study. Non-activated cells
transfected to express TFWt-tGFP exhibited a low level of fXa-generation (Figure 1A). Fur-
thermore, cells expressing tGFP (Figure 1A) or non-transfected cells (not shown) exhibited
little fXa-generation potential. Activation of PAR2 resulted in increased fXa-generation
in HDBEC expressing TF-tGFP, reaching a peak at around 20 min post-activation. The
interaction between TF and fVIIa was robust, and the fXa-generation did not change by
washing out excess fVIIa. Interestingly, no increase in cell-surface TF-tGFP antigen was
observed in endothelial cells at 20 min post-activation (not shown). Moreover, fVIIa-HRP
was capable of binding to cell surface TF-tGFP at similar magnitudes in both non-activated
cells and following PAR2 activation for 20 min (Figure 1B and Table 2). Pre-incubation of
cells with the inhibitory HTF1 antibody significantly reduced fXa-generation (Figure 1C),
indicating the requirement for the TF-fVIIa complex. Together, these data indicate that the
observed elevation in fXa-generation following cell activation was not due to change in
the availability of TF for fVIIa binding. Furthermore, any variations in fXa-generation and
fVIIa-HRP binding did not arise from differences in cell surface expression of the TF-tGFP
variants, demonstrated by the comparable cell-surface TF antigen (Figure 1D).
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Table 2. Analysis of the interaction of fVIIa-HRP with TF-tGFP variants expressed on the cell surface.
TF Variant Non-Activated(Fmol/Million Cells)
PAR2-Activated
(Fmol/Million Cells)
tGFP 11.81 ± 1.19 * 10.2 ± 1.28 *
TFWt-tGFP 20.15 ± 2.56 20.7 ± 2.33
TFSer245-tGFP + PPT siRNA 19.33 ± 1.03 19.51 ± 0.92
TFSer245-tGFP + control siRNA 19.70 ± 0.64 20.01 ± 0.38
TFSer245-tGFP 18.29 ± 2.12 19.6 ± 0.99
TFPhe245-tGFP 17.04 ± 1.59 14.4 ± 1.01 *
TFShortTM-tGFP 18.13 ± 4.04 8.8 ± 2.87 *
TFLongTM-tGFP 20.80 ± 1.50 21.0 ± 1.51
TFPhe241-tGFP 20.00 ± 1.00 20.0 ± 0.82
TFSer242-tGFP 20.00 ± 2.00 19.0 ± 2.50
TFVal225-tGFP 17.00 ± 2.05 12.0 ± 3.10 *
HDBEC were co-transfected to express TFWt-tGFP with PPT or control siRNA. Alternatively, cells were transfected
to express the TF variants as indicated in the table as well as a control set expressing tGFP. The cells were incubated
with fVIIa-HRP for 10 min and washed, and the amount of bound fVII-HRP was determined against a standard
curve. (n = 4, * = p < 0.05 vs. cells expressing TFWt-tGFP.)
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3.3. De-Palmitoylation of Cys245 Is Required for TF-fVIIa Activity but Not Complex Formation
Two approaches were employed in order to examine the role of de-palmitoylation in
the decryption of TF activity. The only palmitoylation site on TF is at Cys245, and PPT1 and
PPT2 are the two identified enzymes shown to be responsible for the de-palmitoylation
of cellular proteins, although controversies exist regarding such proteins [32]. Therefore,
siRNA-mediated knock-down of both PPT1 and PPT2 was optimised to reduce the expres-
sion of these two genes concurrently (Figure 2A). Analysis of PAR2-activated cells previ-
ously transfected to express TFWt-tGFP, together with the PPT-siRNA, showed significantly
reduced fXa-generation following PAR2 activation of HDBEC (Figure 2B,C) and HCAEC
(Supplementary Figure S2) compared to cells transfected with control siRNA. However,
the ability of fVIIa-HRP to interact with cell surface TF-tGFP remained unhindered by the
suppression of PPT expression (Table 2). To confirm these data, the substitution of Cys245
with serine was carried out to prevent the palmitoylation of TF. Conversely, the substitution
of this residue to phenylalanine was used to increase the hydrophobicity of the residue at
position 245 and encourage its incorporation into the membrane. Prevention of TF palmi-
toylation by expressing TFSer245-tGFP significantly increased fXa-generation in resting cells,
compared to TFWt-tGFP (Figure 2D and Supplementary Figure S2). However, the level of
activities converged following activation of cells with PAR2-AP. The ability of fVIIa-HRP
to bind to the cells remained unaffected by Cys245→Ser substitution (Table 2). In contrast,
the expression of TFPhe245-tGFP prevented the increase in fXa-generation following cell
activation but did not alter the residual activity in resting cells (Figure 2E). Additionally,
the ability of fVIIa-HRP to interact with cell surface TFPhe245-tGFP was partially impaired
following activation (Table 2). In agreement with the data generated with transfected-
endothelial cells, siRNA-mediated knock-down of PPT1 and PPT2 in the breast cancer
cell line MDA-MB-231, which constitutively expresses TF, also reduced fXa-generation
(Figure 2F).




Figure 2. Analysis of TF-tGFP procoagulant activity and fVIIa-HRP binding in the presence and absence of TF pal-
mitoylation. (A) HDBEC (5 × 104) were transfected with PPT-siRNA (0–15 pmol) and the expression of PPT1 and -2 meas-
ured by western blot. (B) HDBEC were co-transfected with combinations of pCMV-Ac-TF-tGFP and PPT-siRNA or control 
siRNA, and fXa-generation was measured in resting and PAR2-activated cells. (n = 5, * = p < 0.05 vs. the respective non-
activated sample.) (C) HDBEC were co-transfected to express TF-tGFP, with PPT siRNA or control siRNA. Factor Xa-
generation was measured before and after PAR2 activation for up to 60 min. (n = 4, * = p < 0.05 vs. the respective control 
siRNA sample.) HDBEC were transfected to express (D) TFSer245-tGFP or (E) TFPhe245-tGFP and fXa-generation were meas-
ured as above. (n = 6, * = p < 0.05 vs. the respective cells expressing TFWt-tGFP.) (F) MDA-MB-231 (5 × 104) cells expressing 
endogenous TF were transfected with PPT-siRNA or control siRNA and fXa-generation measured (n = 3, * = p < 0.05 vs. 
cells without siRNA). 
3.4. De-Palmitoylation of Cys245 Promotes the Aggregation of TF on the Cell Membrane 
It has been reported that the procoagulant activity of TF is strongly influenced by the 
membrane microenvironment [21–23]. We hypothesised that de-palmitoylation of TF fol-
lowing cellular activation may sequester TF molecules into specific microdomains within 
the cell membrane. Therefore, the aggregation of TF-tGFP variants before and after cellu-
lar activation was examined by confocal microscopy. These were compared to cells ex-
pressing TFWt-tGFP in which the expression of PPT1 and PPT2 was silenced. Examination 
Figure 2. Cont.
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(A) HDBEC (5× 104) were transfected with PPT-siRNA (0–15 pmol) and the expression of PPT1 and -2 measured by western
blot. (B) HDBEC were co-transfected with combinations of pCMV-Ac-TF-tGFP and PPT-siRNA or control siRNA, and
fXa-generation was measured in resting and PAR2-activated cells. (n = 5, * = p < 0.05 vs. the respective non-activated
sample.) (C) HDBEC were co-transfected to express TF-tGFP, with PPT siRNA or control siRNA. Factor Xa-generation was
measured before and after PAR2 activation for up to 60 min. (n = 4, * = p < 0.05 vs. the respective control siRNA sa ple.)
HDBEC wer transfected to expre s (D) TFS r245-tGFP or (E) TFPhe245-tGFP and fXa-generation were measured as above.
( = 6, * = p < 0.05 vs. he respective cells expressing TFWt-tGFP.) (F) MDA-MB-231 (5 × 104) cells expressing endogenous
TF were transfected with PPT-siRNA or control siRNA and fXa-generation measured (n = 3, * = p < 0.05 vs. cells without
siRNA).
3.4. De-Palmitoylati n of Cys245 Promotes the Aggregation of on he Cell Membrane
It has been reported that the procoagulant activity of TF is strongly influenced by
the membrane microenvironment [21–23]. We hypothesised that de-palmitoylation of TF
following cellular activation may sequester TF molecules into specific microdomains within
the cell membrane. Therefore, the aggregation of TF-tGFP variants before and after cellular
activation was exami ed by confocal micr sc py. hese were compared to cells expressing
TFWt-tGFP in which the expression of PPT1 and PPT2 was silenced. Examination of the
cells indicated an outspread cellular distribution of TFWt-tGFP (Figure 3), which then
aggregated following activation, forming regions with a higher mean diameter (Table 3).
Interestingly, TFSer245-tGFP aggregates were detected even prior to cell activation. In
contrast, expression of TFPhe245-tGFP or suppression of the PPT expression reduced the
ability of the TF protein to form aggregates following PAR2 activation.
Table 3. Estimation of TF aggregate sizes.
Sample Non-Activated (µm) PAR2-Activated (µm)
tGFP 0.09 ± 0.03 0.09 ± 0.03
TFWt-tGFP 0.15 ± 0.06 0.43 ± 0.11
TFSer245-tGFP 0.41 ± 0.10 0.53 ± 0.12
TFPhe245-tGFP 0.09 ± 0.03 0.12 ± 0.05
TFWt-tGFP +PPT siRNA 0.12 ± 0.04 0.12 ± 0.04
HDBEC (5 × 104) were transfected to express TFWt-tGFP in the presence and absence of PPT-siRNA or to express
TFSer245-tGFP or TFPhe245-tGFP as in Figure 3. Sets of cells were then activated for 20 min using PAR2-AP (20 µM),
and the distribution of TF-tGFP was examined. Analysis of the aggregate sizes was carried out using the ImagePro
Plus software.
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Figure 3. Confocal microscopy analysis of TF-tGFP distribution within cells. HDBEC (5 × 104) were transfected to express
TFWt-tGFP in the presence and absence of PPT-siRNA or to express TFSer245-tGFP or TFPhe245-tGFP. Sets of cells were then
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3.5. TF Activity Is Regulated by the Length and Orientation of the Transmembrane Domain
Palmitoylation can adjust the orientation of transmembrane domains within the
membrane by altering the length of the transmembrane domain [33]. This can influence
the location of the protein within the membrane [34–36]. The peptide at the cytoplasmic-
transmembrane interface of TF consists of a sequence of amino acids, which renders two
of the amino acids (Ser241-Leu242) a neutral overall hydrophobicity. We envisaged that
these amino acids may be accommodated equally well within the aqueous cytoplasm and
within the hydrophobic membrane. Consequently, conformational changes within TF,
arising from de-palmitoylation of Cys245, would permit the Ser241-Leu242 motif to be
incorporated into the membrane and therefore lengthen the transmembrane domain by two
amino acids. Deletion of Ser241-Leu242 to shorten the transmembrane domain (TFShortTM-
tGFP) prevented the increase in fXa-generation following PAR2 activation (Figure 4A
and Supplementary Figure S2). Interestingly, the interaction of fVIIa with TFShortTM-tGFP
only declined following cellular activation (Table 2). In contrast, duplicating the motif
to lengthen the transmembrane domain (TFLongTM-tGFP) increased the fXa-generation
potential in resting cells (Figure 4B and Supplementary Figure S2) but had no outcome
on fVIIa binding (Table 2). By substituting Ser241→Phe or alternatively Leu242→Ser, it
was possible to manipulate the hydrophobicity of this region and potentially increase
or decrease the length of the transmembrane region, respectively. Using this approach,
a marginally enhanced level of fXa-generation was detected in resting cells expressing
TFPhe241-tGFP compared to cells expressing TFWT-tGFP, which increased to the same levels
as that of wild-type form upon PAR2 activation (Figure 4C and Supplementary Figure S2).
Moreover, the binding of fVIIa-HRP to TF was unaffected by Ser241→Phe substitution
(Table 2). Basal fXa-generation activity in cells expressing TFSer242-tGFP was comparable
to that of TFWt-tGFP but did not increase following cellular activation (Figure 4D and
Supplementary Figure S2). However, the fVIIa-HRP binding remained unaffected by
Leu242→Ser substitution (Table 2). Finally, the requirement for a flexible transmembrane
domain, capable of accommodating different orientations of the protein, was explored
by substituting Gly225 for a valine residue and therefore reducing the flexibility of the
transmembrane domain. The expression of TFVal225-tGFP supported basal levels of fXa-
generation in resting cells, but again, there was no enhancement in fXa-generation following
PAR2 activation (Figure 4E), which was concurrent with a reduction in fVIIa-HRP binding
ability (Table 2).




Figure 4. The influence of the modifications of TF transmembrane domain on TF activity. HDBEC (5 × 104) were transfected 
to express (A) TFShortTM-tGFP, (B) TFLongTM-tGFP, (C) TFPhe241-tGFP, (D) TFSer242-tGFP or (E) TFVal225-tGFP, and fXa-generation 
was measured. (n = 4, * = p < 0.05 vs. the respective cells expressing TFWt-tGFP.) 
3.6. The Transmembrane Domain Regulates TF Phosphorylation at Ser253 and Incorporation 
into Microvesicles 
De-palmitoylation of TF precedes its phosphorylation at Ser253 [11], which in turn is 
required for the incorporation of TF into microvesicles [13,15]. Therefore, an attempt was 
made to examine the outcome of TF de-palmitoylation and the change in the transmem-
brane domain on the phosphorylation of TF. Cells were transfected with PPT-siRNA to-
gether with TFWt-tGFP or the mutant forms of TF-tGFP described above. TF-tGFP was then 
immunoprecipitated and the phosphorylation state of Ser253 within TF-tGFP was as-
sessed by western blot analysis. Because of immunoprecipitation, ratios were calculated 
against TF antigen, not a housekeeping gene. Moreover, due to the low yield of immuno-
precipitation in HCAEC, only the data from HDBEC have been presented. The suppres-
sion of PPT expression reduced the phosphorylation of TFWt-tGFP at Ser253 following the 
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3.6. The Transmembrane Domain Regulates TF Phosphorylation at Ser253 and Incorporation into
Microvesicl
e-pal itoylation of TF precedes its phosphorylation at Ser253 [11], which in turn
is required for the inc porati n of TF into microvesicles [13,15]. Therefore, an attempt
w s made to examine the outc me of TF de-palmit yl tion and the change in the trans-
membrane domain on the sphorylation of TF. Cells were transfected with PPT-siRNA
together with TFWt-tGFP or the mutant forms of T -tGFP described above. TF-tGFP was
then immunoprecipitated and the sphorylation state of Ser253 within T -tGFP was
assessed by western blot analy is. Because of i munoprecipitation, ratios were calc late
against TF antigen, not a housekeeping gene. Moreover, due to the low yield of immuno-
preci it ti i , only the data from HDBEC have been presented. The suppression
of PPT expr ssion reduce the p os rylation of TFWt-tGFP at Ser253 following the acti-
vation of PAR2 compared to cells transfected with control siRNA (Figure 5A). In addition,
Ser253 was shown to be phosphorylated in non-activated cells expressing TFSer245-tGFP
and further increased following PAR2 activation (Figure 5B,C). In contrast, phosphorylation
of Ser253 was significantly lower in cells expressing TFPhe245-tGFP, even following PAR2 ac-
tivation. Similarly, Ser253 appeared to be phosphorylated in non-activated cells expressing
TFPhe241-tGFP but not in cells expressing TFSer242-tGFP or TFShortTM-tGFP (Figure 5C,D).
Ser253-phosphorylation also increased in TFPhe241-tGFP expressing cells following activa-
tion but was lower in cells expressing TFSer242-tGFP and TFShortTM-tGFP. TFLongTM-tGFP
was not tested in this study. The levels of TF-tGFP incorporated into released microvesi-
cles also reflected the state of Ser253 phosphorylation but not in the same magnitudes
(Figure 5E). Furthermore, the density of released microvesicles was unaltered by the type
of TF mutation (Supplementary Figure S3). Finally, to discriminate between the contribu-
tions of de-palmitoylation and phosphorylation to the fXa-generation associated with cell
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surface TF, HDBEC transfected to express TFWt-tGFP, or alternatively, MDA-MB-231 cells
were pre-incubated with the PKCα inhibitor Gö6976 (100 nM). Inhibition of PKCα with
Gö6976 did not alter fXa-generation in HDBEC expressing TFWt-tGFP (Figure 5F) or in
MDA-MB-231 cells (Figure 5G).
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3.7. Sequential De-Palmitoylation and Phosphorylation of TF Can Co-Ordinate Cell Proliferation
and Apoptosis Following PAR2 Activation
The activation of TF and its interactions with other proteins have been associated
with changes in cell proliferation and the induction of apoptosis. To further elucidate the
mechanisms by which TF mediates these cellular processes, we examined the change in
cell numbers and the level of cellular apoptosis in HDBEC and MCF-7 cells expressing
the TF-tGFP variants as above. For comparison, additional samples were transfected to
express TFAla253-tGFP to prevent TF phosphorylation. Determination of cell numbers
showed increases in cell numbers in both non-activated HDBEC (Figure 6A) and MCF-
7 cells (Figure 6C) on expression of TFSer245-tGFP and TFPhe245-tGFP compared to cells
expressing TFWT-tGFP, but a significant reduction in expression of TFShortTM-tGFP. Fur-
thermore, PAR2 activation of the cells resulted in increased proliferation at 24 h in cells
expressing TFWt-tGFP, TFPhe241-tGFP and TFLongTM-tGFP compared to their respective
control cells expressing tGFP. However, a reduction in the number of both cell types was
observed in PAR2-activated cells expressing TFAla253-tGFP and TFPhe245-tGFP and also in
HDBEC expressing TFSer242-tGFP compared to their respective control cells expressing
tGFP (Figure 6A,C). In agreement with the proliferation data, lower levels of endothelial
but not MCF-7 cell apoptosis was detectable in cells expressing TFWt-tGFP, TFSer245-tGFP,
TFPhe241-tGFP and TFLongTM-tGFP, while increased levels of apoptosis were detected in
endothelial and MCF-7 cells expressing TFAla253-tGFP at 24 h post-activation (Figure 6B,D).
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Figure 6. The influence of TF variants on cell proliferation and apoptosis. HDBEC and MCF-7 cells (2.5 × 104) were
transfected to express the TF variants and were activated with PAR2-AP (20 µM). The rate of cell proliferation (A,C) and cell
apoptosis (B,D) were determined using the crystal violet and a chromogenic apoptosis assay, respectively (n = 3, * = p < 0.05
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4. Discussion
The ability of fVIIa to activate coagulation is dependent on the formation of a complex
with cell-surface TF. However, encrypted TF may form a complex with fVIIa without
promoting significant coagulation [3–8]. The kinetics of these interactions have previously
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been studied [3,22,37]. In agreement with this concept, similar amounts of fVIIa-HRP
were bound to the surface of HDBEC transfected to express TF before and after activation
(Figure 1B and Table 2). Previously, we showed that PAR2 activation of MDA-MB-231
cells resulted in a 56% increase in cell-surface TF antigen at 30 min post-activation [14].
However, endothelial cells exhibit a relatively slower response rate to PAR2 activation
compared to MDA-MB-231 cells [13], and also, the 20 min activation time used in this
study was even shorter than that previously used for MDA-MB-231 cells [14]. Accordingly,
neither the amount of TF-tGFP antigen expressed on the surface of HDBEC (not shown)
nor the binding of fVIIa-HRP changed following PAR2 activation (Table 2). Therefore, the
increases in fXa-generation observed did not arise from changes in cell-surface TF-tGFP
antigen.
Reversible S-palmitoylation of TF was one of the earliest post-translational modifica-
tions reported, and it occurs on Cys245 of human TF [18,19]. Currently, palmitoyl-protein
thioesterase (PPT) 1 and 2 (also known as acyl-protein thioesterase) are the identified
enzymes responsible for the de-palmitoylation of cellular proteins, although controversies
regarding the role, location and number of these enzymes do exist [32,38]. These enzymes
have been implicated in the regulation of proteins as diverse as eNOS [39], p21RAS [40],
PSD-95 [32] and growth-associated protein-43 (GAP-43) [41]. PPT enzymes may be initiated
in response to intracellular Ca2+ ion release [39] and regulate proteins through reversible
de-palmitoylation of cysteine residues [42]. The de-palmitoylation of proteins is a sequence-
specific process [32] and determines the trafficking and localisation of proteins within
cells [43]. Due to the homology between PPT1 and PPT2, we employed a confirmed siRNA
that is suitable for silencing both genes concurrently. The suppression of PPT expression
in cells expressing TFWt-tGFP reduced fXa-generation following the activation of the cells
without affecting fVIIa-HRP binding (Figure 2 and Table 2). However, knock-down of PPT
may have additional unknown effects on cells other than preventing de-palmitoylation of
TF. Therefore, in further studies, palmitoylation of TF was prevented by Cys245→Ser sub-
stitution. This substitution increased fXa-generation in resting cells (Figure 2D), whereas
replacing this residue with phenylalanine to mimic palmitoylation curtailed the increase in
TF procoagulant activity following PAR2 activation (Figure 2E) and partially hindered fVIIa
binding. Therefore, while the ability of TF to bind fVIIa is not altered by its palmitoylation
state, the ability of the complex to generate fXa is significantly amplified following de-
palmitoylation of TF. A possible explanation for this enhanced fXa-generation may include
the translocation of TF to lipid-raft domains that support TF activity through the exposure
of phosphatidylserine on the surface of the cells. This hypothesis is supported by the
suggestion that, following cellular activation, TF translocates across membrane domains of
differing densities [37,44]. The purpose of the various mutational changes and possible
explanations for the main observations have been summarised in Table 4. In fact, TF is
released within low-density microvesicles [30], which must accordingly arise from mem-
brane domains with low density [20,45,46]. Mutations in palmitoyl-protein thioesterase
are known to lead to neurodegenerative disorders [47]. However, different mutations are
thought to result in a broader spectrum of clinical presentations [48,49]. These include
influences on the pro-inflammatory and immune responses [50,51], the apoptotic mech-
anisms [52] and also tumour progression [53]. Therefore, currently any association with
blood haemostasis remains tenuous, and we have refrained from speculation. However, the
availability of PPT knock-out mice [48,54] may produce novel and interesting connections,
particularly regarding the role of TF during the inflammatory responses and/or in cancer
progression [55].
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Table 4. Summary of the purpose of TF modifications and the main observation.
Plasmid Purpose Observation Possible Explanation





pCMV-Ac-TFPhe245-tGFP Mimic palmitoylation ↓TF activation



























pCMV-Ac-TFVal225-tGFP Reduce TMD flexibility ↓TF activation Cannot accommodate
correct structure for
interaction with fVIIa↓fVIIa binding
Activation of cells expressing TFWt-tGFP resulted in the aggregation of TF on cells
(Figure 3, Table 3). Moreover, prevention of palmitoylation induced spontaneous aggre-
gation of TFSer245-tGFP even in resting cells. In contrast, activation of cells did not result
in significant aggregation either in cells expressing TFPhe245-tGFP or in cells following
suppression of PPT1 and PPT2 expression. These findings are in line with those reporting
a lower procoagulant activity associated with palmitoylated TF [11,12,19] arising from
decreased association with cell-surface lipid rafts [5]. The translocation/aggregation of
TF and the association with lipid rafts following de-palmitoylation also suggests alter-
ations in the orientation of the transmembrane domain. Recently, alternative mechanisms
by which palmitoylation can modify receptor protein function have emerged. These are
mainly mediated through adjusting the orientation and length of the transmembrane do-
main [33,36]. Modifications in the length and orientation of the transmembrane domain
allow the incorporation of these membrane proteins into different membrane domains with
varying membrane thickness. In fact, the transmembrane domain of TF consists of 21 amino
acid residues, which is shorter than the average 23 residue length of the integral plasma
membrane proteins [56]. Consequently, an increase in the span of the transmembrane
domain may permit the transfer of TF into thicker lipid-raft domains [33,34,36] and could
result in higher procoagulant activity. The presence of the Ser241-Leu242 di-peptide at the
transmembrane-cytoplasmic interface within TF produces a motif of neutral hydrophobic-
ity (Figure 7). This suggests that these two amino acids may remain within the cytoplasm
or alternatively be buried within the membrane bilayer, depending on other influences
such as palmitoylation of the proximal Cys245 residue. In support of this, increasing the
length of the available membrane-spanning region resulted in higher activity in resting
cells while shortening, and discouraging the incorporation of the di-peptide into the mem-
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brane suppressed the increase in fXa-generation following cellular activation (Figure 4).
Interestingly, the ability of the shortened TF variant to bind fVIIa was significantly reduced
but only following cellular activation, suggesting a robust cellular attempt to translocate
TF to thicker membrane regions, which may in turn disrupt the TF-fVIIa complex due to
steric hindrance. Interference with the TF-fVIIa complex was also observed following the
expression of TFVal225-tGFP to reduce the flexibility at the mid-section of the transmem-
brane domain, also indicating that the TF–fVIIa interaction could not be accommodated. In
previous studies, the expression of truncated forms of TF in cells showed little variation in
activity compared to full-length TF [9,10]. However, these studies measured the TF activity
in activated/perturbed cells only. Our data explain the results obtained using cytoplasmic
domain-deleted TF since the palmitoylation of the cytoplasmic domain appears to be
essential for the encryption rather than the decryption of TF.
De-palmitoylation of TF precedes and enhances the rate of TF phosphorylation [11,12].
The subsequent TF phosphorylation at Ser253 is concurrent with increased TF activity [14]
and release within cell-derived microvesicles [13]. In agreement with a previous re-
port [11], the lack of TF palmitoylation (TFSer245-tGFP) enhanced TF phosphorylation and
release within microvesicles in resting cells (Figure 5). Moreover, encouraging membrane-
incorporation of the transmembrane-cytoplasmic interphase domain (TFPhe241-tGFP) was
equally effective, suggesting that TF phosphorylation at Ser253 is dependent on the length
of the transmembrane domain. In contrast, prevention of de-palmitoylation using either
PPT siRNA or by mimicking palmitoylation (TFPhe245-tGFP) reduced TF phosphorylation
at Ser253 and its release within microvesicles. Furthermore, shortening of the transmem-
brane region by expressing either TFSer242-tGFP or TFShortTM-tGFP equally decreased the
level of TF phosphorylation at Ser253 and reduced TF release (Figure 5). It is possible that
the lengthening of the transmembrane domain permits the approximation of PKCα to
the TF cytoplasmic domain containing Ser253, prior to translocation of TF to lipid-rafts.
However, PKCα has been suggested to be associated with lipid-rafts, which explains how
the translocation of TF to lipid-rafts may promote TF phosphorylation by PKCα. Moreover,
since inhibition of PKCα using Gö6976 did not alter the fXa-generation capacity, our data
suggest that the fXa-generation may be independent of TF phosphorylation and release
from cells.
The expression of TFWt-tGFP induced cell proliferation in both endothelial cells and
the MCF-7 cell line following PAR2-activation (Figure 6). This was concurrent with a
reduction in cell apoptosis in endothelial cells but was not significant in the MCF-7 cell
line. Intriguingly, the expression of TFSer245-tGFP or TFPhe245-tGFP resulted in increased
proliferation in resting cells but declined significantly with TFPhe245-tGFP, following PAR2
activation. This suggests that de-palmitoylation of TF per se, is not a signal for induction of
cell proliferation. Additionally, extending the transmembrane domain (TFPhe241-tGFP or
TFLongTM-tGFP) was highly proliferative following PAR2 activation, while reduced rates of
proliferation were associated with the expression of the shorter TFSer242-tGFP and TFShortTM-
tGFP. Therefore, the induction of cellular proliferation signalling appears to involve the
translocation of TF within the cell membrane and is complemented with a signal arising
from PAR2 activation [13]. The expression of TFWt-tGFP, TFSer245-tGFP, TFPhe241-tGFP
or TFLongTM-tGFP also reduced the rate of cell apoptosis in HDBEC but not MCF-7 cells
(Figure 6). However, the rate of apoptosis did not match the reduction in cell proliferation
observed in cells expressing TFPhe245-tGFP, TFSer242-tGFP and TFShortTM-tGFP. Together,
these data suggest that the induction of apoptosis is likely to be associated with the lack of
phosphorylation of Ser253, and therefore, the impairment in the release of excess TF from
cells and may hence be distinct from the processes that induce proliferation [28,57,58].
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domain from 21 to 23 amino acids.
Cancers 2021, 13, 3837 18 of 20
5. Conclusions
In conclusion, this study indicates that the procoagulant activity of TF may be en-
hanced by the palmitoylation-dependent modifications in the orientation of the trans-
membrane domain of TF and is likely to mobilise TF to particular regions within the
cell membrane. Furthermore, the increase in the procoagulant activity is initiated by de-
palmitoylation and appears to be independent of TF phosphorylation. Finally, following
cellular activation, separate proliferative and pro-apoptotic TF signals are initiated through
phosphorylation-independent and -dependent mechanisms, respectively. At least some of
these mechanisms appear to be independent of the procoagulant function of TF and may
therefore determine the level of damage and the fate of the cells following injury or trauma.
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